Dublin-based pharmaceuticals firm secures cash and stock deal after appeal to Baxalta shareholders
Shire, the London-listed drugs company, has agreed to buy Baxalta $32bn (£22bn) after receiving assurances that it will not face a big tax bill in the US by including cash in its bid.
Shire, which is based in Dublin and managed in Boston, appealled to Baxalta’s shareholders to push for a deal after the board of the rare disease specialist turned down an approach worth $45.32 per share.
Continue reading...from Mergers and acquisitions | The Guardian http://ift.tt/22VfJkt
No comments:
Post a Comment